BioSpace News Archive

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

Sesen Bio today reported operating results for the third quarter ended September 30, 2021.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a presentation on the company’s GEN-1 interleukin 12 (IL-12) immunotherapy program at the Cytokine-Based Cancer Immunotherapies Summit being held in Boston on November 30 to December 2, 2021.

Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopia; additional analyses on DURYSTA®

Hoth Therapeutics, Inc., announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing of the active pharmaceutical ingredient (API) and formulation of drug product for the continued development and commercialization of HT-KIT.

Ascentage Pharma (6855.HK), today announced a clinical trial collaboration and supply agreement with Pfizer Inc. to study the combination of Ascentage Pharma’s lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, in combination with Pfizer’s IBRANCE® (palbociclib).

BERG, the clinical stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced their participation at the Society for Neuroscience (SfN) Annual Meeting from November 8-11, 2021.

Potrero Medical, innovator of the Accuryn Monitoring System, announced the launch of its newest software App for the Accuryn™ Monitor and AccuTab™.

LivaNova PLC today announced it will host a virtual Investor Day on December 7 from 8 a.m.–12 p.m. Central Time (9 a.m.–1 p.m. Eastern Time).

Boehringer Ingelheim today announced that the first patient has enrolled in a new clinical study to observe whether COVID-19 patients with respiratory failure are more susceptible to developing progressive Interstitial Lung Disease (ILD), or scarring of the lungs.